 Although the well known Toll like receptor 9 agonist CpGODN has shown promising results as vaccine adjuvant in preclinical and clinical studies its

@highlight Delivery system combines synergistically protein adjuvant conjugate and liposomes.
@highlight Immune response was dramatically improved compared to previously published data.
@highlight Pathogen Group B
@highlight was used as model for which there is no vaccine yet.
@highlight The methodology could be extended to other agonists adjuvant liposome formulations.
